190 related articles for article (PubMed ID: 16480264)
1. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors.
Peifer C; Stoiber T; Unger E; Totzke F; Schächtele C; Marmé D; Brenk R; Klebe G; Schollmeyer D; Dannhardt G
J Med Chem; 2006 Feb; 49(4):1271-81. PubMed ID: 16480264
[TBL] [Abstract][Full Text] [Related]
2. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors.
Peifer C; Selig R; Kinkel K; Ott D; Totzke F; Schächtele C; Heidenreich R; Röcken M; Schollmeyer D; Laufer S
J Med Chem; 2008 Jul; 51(13):3814-24. PubMed ID: 18529047
[TBL] [Abstract][Full Text] [Related]
4. Profile and molecular modeling of 3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1 H-pyrrole-2,5-dione (1) as a highly selective VEGF-R2/3 inhibitor.
Peifer C; Krasowski A; Hämmerle N; Kohlbacher O; Dannhardt G; Totzke F; Schächtele C; Laufer S
J Med Chem; 2006 Dec; 49(25):7549-53. PubMed ID: 17149885
[TBL] [Abstract][Full Text] [Related]
5. 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.
Wissner A; Floyd MB; Johnson BD; Fraser H; Ingalls C; Nittoli T; Dushin RG; Discafani C; Nilakantan R; Marini J; Ravi M; Cheung K; Tan X; Musto S; Annable T; Siegel MM; Loganzo F
J Med Chem; 2005 Dec; 48(24):7560-81. PubMed ID: 16302797
[TBL] [Abstract][Full Text] [Related]
6. 1-(Azolyl)-4-(aryl)-phthalazines: novel potent inhibitors of VEGF receptors I and II.
Kiselyov AS; Semenova M; Semenov VV; Piatnitski EL
Chem Biol Drug Des; 2006 Nov; 68(5):250-5. PubMed ID: 17177884
[TBL] [Abstract][Full Text] [Related]
7. Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases.
Miyazaki Y; Nakano M; Sato H; Truesdale AT; Stuart JD; Nartey EN; Hightower KE; Kane-Carson L
Bioorg Med Chem Lett; 2007 Jan; 17(1):250-4. PubMed ID: 17027260
[TBL] [Abstract][Full Text] [Related]
8. Aryl-indolyl maleimides as inhibitors of CaMKIIdelta. Part 1: SAR of the aryl region.
Levy DE; Wang DX; Lu Q; Chen Z; Perumattam J; Xu YJ; Liclican A; Higaki J; Dong H; Laney M; Mavunkel B; Dugar S
Bioorg Med Chem Lett; 2008 Apr; 18(7):2390-4. PubMed ID: 18334294
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.
Potashman MH; Bready J; Coxon A; DeMelfi TM; DiPietro L; Doerr N; Elbaum D; Estrada J; Gallant P; Germain J; Gu Y; Harmange JC; Kaufman SA; Kendall R; Kim JL; Kumar GN; Long AM; Neervannan S; Patel VF; Polverino A; Rose P; Plas Sv; Whittington D; Zanon R; Zhao H
J Med Chem; 2007 Sep; 50(18):4351-73. PubMed ID: 17696416
[TBL] [Abstract][Full Text] [Related]
10. Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.
Harris PA; Cheung M; Hunter RN; Brown ML; Veal JM; Nolte RT; Wang L; Liu W; Crosby RM; Johnson JH; Epperly AH; Kumar R; Luttrell DK; Stafford JA
J Med Chem; 2005 Mar; 48(5):1610-9. PubMed ID: 15743202
[TBL] [Abstract][Full Text] [Related]
11. 2-Hydroxy-4,6-diamino-[1,3,5]triazines: a novel class of VEGF-R2 (KDR) tyrosine kinase inhibitors.
Baindur N; Chadha N; Brandt BM; Asgari D; Patch RJ; Schalk-Hihi C; Carver TE; Petrounia IP; Baumann CA; Ott H; Manthey C; Springer BA; Player MR
J Med Chem; 2005 Mar; 48(6):1717-20. PubMed ID: 15771417
[TBL] [Abstract][Full Text] [Related]
12. Aryl-indolyl maleimides as inhibitors of CaMKIIdelta. Part 2: SAR of the amine tether.
Levy DE; Wang DX; Lu Q; Chen Z; Perumattam J; Xu YJ; Higaki J; Dong H; Liclican A; Laney M; Mavunkel B; Dugar S
Bioorg Med Chem Lett; 2008 Apr; 18(7):2395-8. PubMed ID: 18334295
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
Dandu R; Zulli AL; Bacon ER; Underiner T; Robinson C; Chang H; Miknyoczki S; Grobelny J; Ruggeri BA; Yang S; Albom MS; Angeles TS; Aimone LD; Hudkins RL
Bioorg Med Chem Lett; 2008 Mar; 18(6):1916-21. PubMed ID: 18308565
[TBL] [Abstract][Full Text] [Related]
14. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.
Borzilleri RM; Bhide RS; Barrish JC; D'Arienzo CJ; Derbin GM; Fargnoli J; Hunt JT; Jeyaseelan R; Kamath A; Kukral DW; Marathe P; Mortillo S; Qian L; Tokarski JS; Wautlet BS; Zheng X; Lombardo LJ
J Med Chem; 2006 Jun; 49(13):3766-9. PubMed ID: 16789733
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of prodrugs for anti-angiogenic pyrrolylmethylidenyl oxindoles.
Maskell L; Blanche EA; Colucci MA; Whatmore JL; Moody CJ
Bioorg Med Chem Lett; 2007 Mar; 17(6):1575-8. PubMed ID: 17254788
[TBL] [Abstract][Full Text] [Related]
16. Aryl-indolyl maleimides as inhibitors of CaMKIIdelta. Part 3: Importance of the indole orientation.
Lu Q; Chen Z; Perumattam J; Wang DX; Liang W; Xu YJ; Do S; Bonaga L; Higaki J; Dong H; Liclican A; Sideris S; Laney M; Dugar S; Mavunkel B; Levy DE
Bioorg Med Chem Lett; 2008 Apr; 18(7):2399-403. PubMed ID: 18337095
[TBL] [Abstract][Full Text] [Related]
17. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial activity of a novel series of 3-bromo-4-(1H-3-indolyl)-2,5-dihydro-1H-2,5-pyrroledione derivatives--an extended structure-activity relationship study.
Mahboobi S; Eichhorn E; Winkler M; Sellmer A; Möllmann U
Eur J Med Chem; 2008 Mar; 43(3):633-56. PubMed ID: 17624634
[TBL] [Abstract][Full Text] [Related]
19. Arylthioindole inhibitors of tubulin polymerization. 3. Biological evaluation, structure-activity relationships and molecular modeling studies.
La Regina G; Edler MC; Brancale A; Kandil S; Coluccia A; Piscitelli F; Hamel E; De Martino G; Matesanz R; Díaz JF; Scovassi AI; Prosperi E; Lavecchia A; Novellino E; Artico M; Silvestri R
J Med Chem; 2007 Jun; 50(12):2865-74. PubMed ID: 17497841
[TBL] [Abstract][Full Text] [Related]
20. Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase.
Piatnitski EL; Duncton MA; Kiselyov AS; Katoch-Rouse R; Sherman D; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
Bioorg Med Chem Lett; 2005 Nov; 15(21):4696-8. PubMed ID: 16143524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]